公开(公告)号：KR1020090132264A

公开(公告)日：2009-12-30

申请号：KR1020080058448

申请日：2008-06-20

Applicant: 덕성여자대학교 산학협력단

Inventor： 문애리 ,  김명옥 ,  황진선

IPC: A61K38/16 ,  A61K39/395 ,  A61K48/00 ,  A61P35/00

CPC classification number: A61K39/3955 ,  A61K38/1709 ,  C07K14/4703

Abstract: PURPOSE: A composition for anticancer containing an inhibitor for flotillin protein or gene is provided to relate to down regulation of signal transduction of Ras protein. CONSTITUTION: A composition for anticancer contains flotillin protein or gene encoding the protein. The flotillin protein has amino acid sequence of sequence number 1. The flotillin gene has sequence of sequence number 2. A flotillin inhibitor is an antibody specifically binding to the flotillin protein. The antibody is monoclonal antibody, polyclonal antibody, mono chain antibody, chimera antibody or peptide mimetics. The composition further contains an apoptosis inducer.

Abstract translation: 目的：提供一种含有浮游蛋白或基因抑制剂的抗癌组合物，用于下调Ras蛋白信号转导。 构成：抗癌组合物含有浮游蛋白蛋白或编码蛋白质的基因。 蛋白酶蛋白具有序列号1的氨基酸序列。酶切基因具有序列号2的序列。酶联蛋白抑制剂是与蛋白酶特异性结合的抗体。 抗体是单克隆抗体，多克隆抗体，单链抗体，嵌合体抗体或肽模拟物。 组合物还含有凋亡诱导剂。

公开(公告)号：KR1020130009084A

公开(公告)日：2013-01-23

申请号：KR1020110069920

申请日：2011-07-14

Applicant: 덕성여자대학교 산학협력단

Inventor： 문애리 ,  송재인 ,  강유진 ,  용해영 ,  김영중

IPC: A61K36/8984 ,  A61K31/015 ,  A61P35/00

CPC classification number: A61K31/122 ,  A61K36/8984

Abstract: PURPOSE: A pharmaceutical composition containing a Dendrobium moniliforme extract and denbinobin for anti-gastric cancer is provided to suppress expression of S100A8 protein and reduce infiltration. CONSTITUTION: A pharmaceutical composition for anti-gastric cancer contains a Dendrobium moniliforme extract and a pharmaceutically acceptable salt as an active ingredient. The pharmaceutical composition for anti-gastric cancer contains denbinobin and a pharmaceutically acceptable carrier as an active ingredient. The therapeutically effective amount of denbinobin is 0.01-25%. Denbinobin is extracted from Dendrobium moniliforme or chemically synthesized. The pharmaceutical composition is used by oral administration or parenteral administration.

Abstract translation: 目的：提供含有石斛龙骨提取物和丹参素用于抗胃癌的药物组合物，以抑制S100A8蛋白的表达并减少浸润。 构成：用于抗胃癌的药物组合物含有石斛提取物和药学上可接受的盐作为活性成分。 用于抗胃癌的药物组合物含有丹参蛋白和药学上可接受的载体作为活性成分。 丹参素的治疗有效量为0.01〜25％。 丹参素从石斛石斛提取或化学合成。 药物组合物通过口服给药或肠胃外给药使用。

公开(公告)号：KR101024171B1

公开(公告)日：2011-03-22

申请号：KR1020080058448

申请日：2008-06-20

Applicant: 덕성여자대학교 산학협력단

Inventor： 문애리 ,  김명옥 ,  황진선

IPC: A61K38/16 ,  A61K39/395 ,  A61K48/00 ,  A61P35/00

Abstract: 본 발명은 항암용 조성물, 보다 상세하게는 Ras 단백질의 하부 신호전달 경로에 관여하는 플로틸린 단백질 또는 이를 코딩하는 유전자에 대한 억제제를 유효성분으로 포함하는 항암용 조성물에 관한 것으로서, 본 발명의 항암용 조성물은 암 증상의 예방, 치료 및 개선에 유용하게 사용될 수 있다.
Ras, 플로틸린, 신호전달, 아폽토시스

公开(公告)号：KR1020090072132A

公开(公告)日：2009-07-02

申请号：KR1020070140139

申请日：2007-12-28

Applicant: 덕성여자대학교 산학협력단

Inventor： 문애리 ,  용해영

IPC: C07K19/00 ,  C12N15/62 ,  C12N15/09

Abstract: A Ras fusion protein, which a part of N-Ras protein and a part of H-Ras protein are combined, is provided to identify interaction between Ras protein signal pathway and cancer generation and develop the molecule target cancer theraphy. A Ras fusion protein has a form which the first to nth amino acid of a N-Ras (neuroblastoma-Ras) protein and n+1th to 189th amino acid of H-Ras(Harvey-Ras) protein are combined, and n is integer under 165. The fusion protein has the combination form of 1-120th amino acid of N-Ras protein and 121-189th amino acid of H-Ras protein. The fusion protein has the combination form of 1-141th amino acid of N-Ras protein and 142-189th amino acid of H-Ras protein. The fusion protein has the combination form of 1-165th amino acid of N-Ras protein and 166-189th amino acid of the H-Ras protein. The 12th amino acid of the fusion protein is substituted with Asp for Gly.

Abstract translation: 提供Ras融合蛋白，其一部分N-Ras蛋白和部分H-Ras蛋白被组合，以鉴定Ras蛋白信号通路与癌症生成之间的相互作用并开发分子靶标癌症。 Ras融合蛋白具有N-Ras（神经母细胞瘤-Ras）蛋白的第一至第n个氨基酸和H-Ras（Harvey-Ras）蛋白的n + 1至189个氨基酸的组合形式，并且n是整数 融合蛋白具有N-Ras蛋白的第1-120个氨基酸和H-Ras蛋白的第121-189个氨基酸的组合形式。 融合蛋白具有N-Ras蛋白的第1-141位氨基酸和H-Ras蛋白的第142-189位氨基酸的组合形式。 融合蛋白具有N-Ras蛋白1-165位氨基酸和H-Ras蛋白166-189位氨基酸的组合形式。 融合蛋白的第12个氨基酸被Asp取代为Gly。

公开(公告)号：KR1020080042333A

公开(公告)日：2008-05-15

申请号：KR1020060110598

申请日：2006-11-09

Applicant: 덕성여자대학교 산학협력단

Inventor： 문애리 ,  강소욱

IPC: A61K31/366 ,  A61P35/00

Abstract: A pharmaceutical composition containing simvastatin is provided to reduce the invasion of a breast cancer cell line, the expression of MMP-2 and MMP-9 related to the invasion, and activity of intracellular signal molecules related to cell mobility and invasion, so that the composition is useful for treatment of breast cancer and its metastasis. A pharmaceutical composition for treatment of breast cancer contains simvastatin which inhibits activity of GTPase associated with metastasis including Raf-1 or Rac, or phosphorylation of intracellular molecules related to cell metastasis including ERK(extracellular signal-regulated protein kinase), MKK(mitogen-activated protein kinase kinase), MEK(MAP kinase/ERK kinase), PI(3)K(phosphatidylinositol-3-kinase) or Akt, wherein the daily dosage of simvastatin is 0.1-20 mg/kg, preferably 1-10 mg/kg.

Abstract translation: 提供含有辛伐他汀的药物组合物，以减少乳腺癌细胞系侵袭，与侵袭有关的MMP-2和MMP-9的表达，以及与细胞迁移和侵袭有关的细胞内信号分子的活性，使得组合物 可用于治疗乳腺癌及其转移。 用于治疗乳腺癌的药物组合物含有辛伐他汀，其抑制与包括Raf-1或Rac相关的转移的GTP酶的活性，或与细胞转移相关的细胞内分子的磷酸化（包括ERK（细胞外信号调节蛋白激酶）），MKK（丝裂原活化的 蛋白激酶激酶），MEK（MAP激酶/ ERK激酶），PI（3）K（磷脂酰肌醇-3-激酶）或Akt，其中辛伐他汀的日剂量为0.1-20mg / kg，优选1-10mg / kg 。